Royal Bank Of Canada Increases Prothena (NASDAQ:PRTA) Price Target to $12.00

Prothena (NASDAQ:PRTA) had its price target lifted by analysts at Royal Bank Of Canada from $11.00 to $12.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 33.04% from the company’s current price.

Other research analysts have also recently issued research reports about the stock. UBS Group set a $36.00 price objective on shares of Prothena in a research report on Tuesday, October 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prothena in a research note on Monday, December 29th. HC Wainwright upped their price target on shares of Prothena from $20.00 to $30.00 and gave the company a “buy” rating in a report on Friday, November 7th. Citizens Jmp set a $19.00 price objective on shares of Prothena in a research note on Monday, December 1st. Finally, Piper Sandler boosted their target price on Prothena from $15.00 to $36.00 and gave the company an “overweight” rating in a research report on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Prothena currently has an average rating of “Hold” and an average price target of $22.00.

Prothena Stock Performance

Shares of PRTA stock opened at $9.02 on Friday. The firm has a market cap of $485.55 million, a P/E ratio of -1.99, a P/E/G ratio of 1.91 and a beta of -0.11. Prothena has a fifty-two week low of $4.32 and a fifty-two week high of $16.67. The business’s 50 day moving average price is $9.26 and its 200-day moving average price is $9.41.

Prothena (NASDAQ:PRTA) last released its earnings results on Thursday, February 19th. The biotechnology company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.05. Prothena had a negative return on equity of 62.53% and a negative net margin of 2,520.57%.The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.67 million. As a group, equities analysts predict that Prothena will post -4.04 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PRTA. Rubric Capital Management LP increased its holdings in Prothena by 138.7% during the 4th quarter. Rubric Capital Management LP now owns 3,677,331 shares of the biotechnology company’s stock worth $35,119,000 after purchasing an additional 2,136,958 shares during the period. State Street Corp increased its stake in shares of Prothena by 151.7% during the fourth quarter. State Street Corp now owns 2,267,802 shares of the biotechnology company’s stock valued at $21,658,000 after buying an additional 1,366,764 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Prothena during the second quarter valued at $6,176,000. Rangeley Capital LLC bought a new stake in shares of Prothena in the second quarter valued at about $4,342,000. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Prothena in the third quarter valued at about $6,386,000. Institutional investors own 97.08% of the company’s stock.

Key Prothena News

Here are the key news stories impacting Prothena this week:

• Positive Sentiment: Q4 EPS slightly beat consensus (GAAP loss per share modestly narrower than expected), showing improvement versus a year ago — a near‑term positive signal for financial trajectory. Prothena Press Release (Q4 & FY2025)
• Positive Sentiment: Analyst support: RBC raised its price target from $11 to $12 (sector perform), implying meaningful upside from current levels — this can provide some analyst‑driven buying interest. Benzinga
• Neutral Sentiment: Management highlighted upcoming partner milestones and program catalysts for 2026; these are potential positive binary events but timing/outcomes remain uncertain. Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
• Neutral Sentiment: Full earnings call transcript and highlights are available for investors to parse program updates and management tone — useful for judging near‑term execution risk. Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: Revenue missed materially ($0.02M reported vs. ~$0.67M expected), underscoring current lack of commercial receipts and heightening sensitivity to financing and partnership milestones. Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Company provided 2026 cash‑burn guidance (planned spend and runway), which may pressure shares if investors see a need for near‑term equity financing or dilution. Business Wire — Q4 & FY2025 Results and Guidance

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.